| First Author | Ishida N | Year | 2024 |
| Journal | Int J Med Sci | Volume | 21 |
| Issue | 8 | Pages | 1461-1471 |
| PubMed ID | 38903922 | Mgi Jnum | J:360558 |
| Mgi Id | MGI:7834534 | Doi | 10.7150/ijms.94938 |
| Citation | Ishida N, et al. (2024) Dasatinib promotes muscle differentiation and disrupts normal muscle regeneration. Int J Med Sci 21(8):1461-1471 |
| abstractText | Dasatinib is one of the second-generation tyrosine kinase inhibitors used to treat chronic myeloid leukemia and has a broad target spectrum, including KIT, PDGFR, and SRC family kinases. Due to its broad drug spectrum, dasatinib has been reported at the basic research level to improve athletic performance by eliminating senescent cell removal and to have an effect on muscle diseases such as Duchenne muscular dystrophy, but its effect on myoblasts has not been investigated. In this study, we evaluated the effects of dasatinib on skeletal muscle both under normal conditions and in the regenerating state. Dasatinib suppressed the proliferation and promoted the fusion of C2C12 myoblasts. During muscle regeneration, dasatinib increased the gene expressions of myogenic-related genes (Myod, Myog, and Mymx), and caused abnormally thin muscle fibers on the CTX-induced muscle injury mouse model. From these results, dasatinib changes the closely regulated gene expression pattern of myogenic regulatory factors during muscle differentiation and disrupts normal muscle regeneration. Our data suggest that when using dasatinib, its effects on skeletal muscle should be considered, particularly at regenerating stages. |
